Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nightmares and Night Terrors01:18

Nightmares and Night Terrors

Nightmares and night terrors represent two distinct types of sleep disturbances that differ in timing, characteristics, and the sleeper's recall of the event. Nightmares are vivid, disturbing dreams that usually awaken the sleeper from REM sleep, a stage of sleep where brain activity is high, and dreams are most frequent. Upon awakening, individuals often have detailed recollections of their nightmares, which can include themes of threats to survival, security, or self-esteem.
Nightmares often...
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
Management of Insomnia01:19

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Pharmacokinetic Characteristics of Long‑Acting Injectable Antipsychotics for Schizophrenia: An Overview.

CNS drugs·2024
Same author

Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality.

BMC psychiatry·2023
Same author

Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".

Journal of psychopharmacology (Oxford, England)·2022
Same author

Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression.

Neuropsychiatric disease and treatment·2022
Same author

Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes.

Therapeutic advances in psychopharmacology·2022
Same author

Patient profiles, initial hospital encounter characteristics, and hospital re-encounters of patients with a hospital emergency department visit or inpatient admission for major depressive disorder.

Journal of medical economics·2022

Related Experiment Video

Updated: Jul 17, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Mirtazapine-induced nightmares

Maju Mathews, Biju Basil, Harun Evcimen

    Primary Care Companion to the Journal of Clinical Psychiatry
    |January 25, 2007
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
    08:20

    MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

    Published on: August 11, 2015

    Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
    07:35

    Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

    Published on: July 8, 2025

    Related Experiment Videos

    Last Updated: Jul 17, 2026

    Pentylenetetrazole-Induced Kindling Mouse Model
    07:06

    Pentylenetetrazole-Induced Kindling Mouse Model

    Published on: June 12, 2018

    MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
    08:20

    MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

    Published on: August 11, 2015

    Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
    07:35

    Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

    Published on: July 8, 2025